BioMed Research International

Research Article

[Retracted] Serum Fetuin-A Levels in Patients with Cardiovascular Disease: A Meta-Analysis

Table 1

Characteristics of included studies focused on serum levels of FA.
First authorYearEthnicitySample sizeGender (M/F)Age (years)DiseaseMethodMain findingMean value (ug/mL)NOS score
CaseControlCaseControlCaseControl(Case versus control)
Kadoglou [20]2014Caucasians953568/2728/767.1 ± 6.565.0 ± 9.5CADELISA①222.00 versus 839 7
Zhao [10]2013Asians1296967/6235/3463.1 ± 8.962.9 ± 9.0CAD with T2DMELISA②451.14 versus 396.417
   1296967/6235/3463.1 ± 8.962.9 ± 9.0CAD with T2DMELISA 451.14 versus 308.3 
Ballestri [21]2013Caucasians462435/1113/1167.6 ± 11.468.9 ± 13.6CADELISA③374 versus 445.86
Voros [23]2012Caucasians17181120/5146/3562.0 ± 6.060.0 ± 7.0MIRIA④673 versus 6738
Afsar [24]2012Asians958168/2732/4961.8 ± 12.148.3 ± 9.2ACSELISA⑤760 versus 11007
Basar [19]2011Asians18055152/2846/957.9 ± 9.456.7 ± 8.2STEMIELISA⑥286.85 versus 359.88
Bilgir [25]2010Asians3442——60.3 ± 11.859.6 ± 11.9MIELISA⑦156 versus 1795
       59.4 ± 8.859.6 ± 11.9SAELISA 167 versus 179  
Weikert [26]2008Caucasians2272198164/63798/140057.5 ± 0.649.5 ± 0.2MIELISA⑧253.6 versus 226.98
Lim [22]2007Caucasians28434233/5120/1460.0 ± 14.067.0 ± 14.0STEMIELISA⑨188 versus 2198
Mathews [27]2002Caucasians204414/623/2155 (43~69)48 (38~62)AMIELISA⑩281.3 versus 312.36
FA: fetuin-A; M: male; F: female; CAD: coronary artery disease; MI: myocardial infarction; ACS: acute coronary syndrome; STEMI: ST-elevation myocardial infarction; SA: stable angina; AMI: acute myocardial infarction; NOS: Newcastle-Ottawa Scale; ①: derangements in serum levels of all vascular calcification inhibitors compared with those in healthy controls. Simvastatin treatment for 6 months significantly decreased serum fetuin-A, OPG, and OPN levels; ②: serum fetuin-A levels are independently correlated with the presence and severity of CAD in T2DM patients; ③: high fetuin-A levels are independently associated with NAFLD and a lower risk of chronographically diagnosed CAD; ④: ghrelin level is determined by elevated insulin and decreased adiponectin levels; ⑤: fetuin-A levels decrease in patients with acute coronary syndromes, independent of heart valve calcification; ⑥: low-admission fetuin-A levels are associated with impaired coronary flow in STEMI patients undergoing primary percutaneous coronary intervention; ⑦: fetuin-A levels seem to be decreased in SA and MI patients; ⑧: high plasma fetuin-A levels are correlated with an increased risk of MI and IS; ⑨: fetuin-A is an important predictor of death at 6 months in STEMI patients independent of NT-proBNP, CRP, and CADILLAC risk score; ⑩: Plasmaa2-HSG concentrations start to decrease within a few hours after the onset of AMI and return to near normal concentrations during the recovery period (5–7 days after AMI).